Core Laboratories (CLB) has wrapped up FY 2025 with fourth quarter revenue of US$138.3 million, basic EPS of US$0.11 and net income of US$4.9 million, setting the tone for how investors read the full year. Over the past four quarters, the company has seen revenue move from US$123.6 million in Q1 2025 to US$138.3 million in Q4 2025, while quarterly EPS ranged from a small loss of US$0.00 in Q1 to US$0.31 in Q3 and US$0.11 in Q4, leaving investors focused on how consistently the business can convert that top line into stable margins.

See our full analysis for Core Laboratories.

With the headline numbers on the table, the next step is to set these results against the main market narratives around Core Laboratories to see which stories hold up and which start to look stretched.

Margins Settle Around 5.6% After A Bumpy Year

• On a trailing basis, Core Laboratories earned US$29.7 million of net income on US$526.5 million of revenue, which works out to a 5.6% net profit margin compared with 6.0% in the prior year.
• Bulls point to five year earnings growth of 28.7% a year as evidence that profitability is on a stronger long term footing, yet the recent margin slippage tests how durable that story really is.
  • That 5.6% trailing margin sits slightly below last year’s 6.0%, so even with higher quarterly revenue in FY 2025, each dollar of sales translated into a bit less profit than before.
  • The move from a small Q1 loss of US$0.2 million to Q3 net income of US$14.2 million shows the business can be profitable, but the Q4 net income of US$4.9 million underlines that margins are not yet consistently at the higher end of the bulls’ expectations.

Bulls argue that if Core can sustain margins closer to the high points seen during the year, the multi year earnings growth story remains intact, and you can see how that optimism ties back to the detailed bull case here 🐂 Core Laboratories Bull Case.

P/E Of 24.4x Versus Peers And A Tough DCF Check

• The stock trades on a trailing P/E of 24.4x, below the Energy Services industry average of 28.2x and the peer average of 35.4x, while the current share price of US$15.71 sits well above the DCF fair value of US$3.69 that comes from the trailing cash flow based model.
• Critics highlight that a lower P/E ratio does not automatically signal a bargain when the cash flow model points to a very large gap between price and estimated value.
  • The 24.4x P/E suggests the market is paying less per dollar of earnings than it pays for peers, yet the share price is more than 4x the DCF fair value of US$3.69, which lines up more with the cautious narrative than with a simple “cheap on P/E” story.
  • Bears can also point out that trailing net margin has eased from 6.0% to 5.6%, so the earnings that support that P/E multiple are coming from slightly thinner profitability than a year ago.

Skeptics warn that when a stock screens cheaper on P/E but rich versus DCF fair value, it pays to read the bear case in full before drawing conclusions 🐻 Core Laboratories Bear Case.

Quarterly EPS Swings Versus Five Year Growth

• Across FY 2025, basic EPS moved from a small loss in Q1 to US$0.23 in Q2, peaked at US$0.31 in Q3 and then eased to US$0.11 in Q4, while trailing twelve month EPS for Q4 2025 came in at US$0.64 compared with US$0.67 a year earlier.
• The consensus narrative leans on that 28.7% annual earnings growth over five years and a trailing EPS of roughly US$0.64 to argue that shorter term EPS swings need to be weighed against a longer track record.
  • The step up in quarterly revenue from US$123.6 million in Q1 2025 to US$138.3 million in Q4 shows the top line held up even as EPS moved around, which fits the view that the business can support multi year earnings, but with some lumpiness.
  • At the same time, trailing net income of US$29.7 million in the latest twelve month period sits below the US$32.1 million level seen one quarter earlier on a trailing basis, which gives the more cautious voices in the consensus some support when they talk about recent pressure on profitability.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Core Laboratories on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Reading through the mixed signals on margins, earnings and valuation, it helps to move quickly from headlines to the underlying data and form your own view. To see what is driving the optimistic angle around the company, take a closer look at the 1 key reward.

See What Else Is Out There

Core Laboratories is working with thinner profit margins, uneven quarterly EPS and a share price that screens rich against a trailing DCF model.

If those gaps between earnings quality and valuation concern you, broaden your research and hunt for companies that look cheaper on fundamentals using the 59 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.